Core 2: Bioinformatics and Genomics for Cancer Research
Official title: Core 2: Bioinformatics/Biostatistics/Genomics
Funded at Sanford Burnham Prebys Medical Discovery Institute · NIH-11418974 · Data updated 2026-11-12
A cancer-focused team uses advanced computing and genomics to map mutations and pathways, build an integrated data platform, and guide future personalized approaches.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sanford Burnham Prebys Medical Discovery Institute NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | September 9, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $289,595 |
| NIH project number | 5P01CA281819-03 |
| Project ID | NIH-11418974 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with various cancers whose tumors can be profiled through sequencing and studied via biospecimens or patient-derived models.
✕Less likely to help
Patients whose tumors are not available for sequencing or for whom biospecimen collection is not feasible may not benefit.
What this research studies
This project centers on Core 2, which provides centralized support for bioinformatics, biostatistics, genomics, transcriptomics, and computational biology. It aims to create an integrated analytical platform that unites methods and tools from multiple projects to enable both broad discovery and targeted analyses. Researchers will analyze sequencing data to understand somatic mutations, clonal evolution, and mutational signatures under metabolic stresses. The core will also link biospecimens, organoids, patient-derived models, and their data to identify novel pathways and interactions among NRF2, ATF6, SAB, and other biomarkers. The work is designed to translate complex data into clearer insights that could inform cancer treatment strategies.
Why it matters
Potential benefit: Could accelerate discovery of cancer biomarkers and pathways that may lead to new diagnostic and treatment options.
How similar studies have gone: Other cancer genomics projects have successfully linked mutations and pathways to potential therapeutic targets, though this core emphasizes data integration and platform development.
Where this research is happening
-
Sanford Burnham Prebys Medical Discovery Institute
La Jolla, United States Active
Researchers
- Principal investigator: Tamayo, Pablo — Sanford Burnham Prebys Medical Discovery Institute
- Study coordinator: Tamayo, Pablo
Related research
Other NIH-funded projects on the same topics.
-
Aging and liver cancer: new ways to prevent and fight hepatocellular carcinoma
This research explores how aging promotes liver cancer and tests new preventive approaches that could help people at higher risk due to age.
-
EPHA2 signaling and breast cancer spread tied to the body’s stiffness
This grant explores how the EPHA2 receptor helps breast cancer cells respond to the stiffness of their surroundings and whether activating EPHA2’s normal signaling can block cancer invasion.
-
Molecule-focused study on soluble TREM2 in Alzheimer's disease
A study to understand how soluble TREM2 in the brain and spinal fluid may influence Alzheimer's disease in people with the condition or at risk for it.
-
How NRF2 and FBP1 control liver metabolism
This work looks at whether changes in two liver proteins, NRF2 and FBP1, help explain low blood sugar and fat buildup in the liver for people with metabolic liver problems or rare FBP1 deficiency.
-
How mitochondrial and immune signals drive inflammation linked to Alzheimer's
This project looks at how damaged mitochondria and immune signaling cause inflammation that may contribute to Alzheimer's disease.
-
Nup210’s role in leukemia and its potential as a target
A doctor-scientist team is studying how a protein called Nup210 helps a type of blood cancer (AML) grow, with the goal of finding new ways to predict outcomes and treat the disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.